{
    "doi": "https://doi.org/10.1182/blood.V110.11.173.173",
    "article_title": "Comparison of Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning with HLA-Matched Related (MRD), Unrelated (URD), and Related Haploidentical (Haplo) Donors for Relapsed or Refractory Hodgkin Lymphoma (HL). ",
    "article_date": "November 16, 2007",
    "session_type": "Clinical Results - Alternative Donor Transplantation",
    "abstract_text": "We evaluated the utility of allogeneic HCT using nonmyeloablative conditioning as a potential treatment option for 79 patients (pts) with HL who were ineligible for high dose conventional allogeneic HCT and compared outcome based on donor cell source (MRD n=34, URD n=24, Haplo n=21). Conditioning consisted of 2 Gy TBI alone (n=15, MRD) or combined with either 90 mg/m 2 (MRD n=19, all URD) or 150 mg/m 2 (all Haplo) fludarabine. All haplo recipients also received cyclophosphamide pre (29 mg/kg) and post (50 or 100 mg/kg) HCT. GVHD prophylaxis consisted of mycophenolate mofetil and a calcineurin inhibitor. Pts were heavily pretreated with a median number of 5 (range, 2\u201310) prior regimens. Most pts failed prior autologous HCT (91%) and radiation therapy (86%). There were no graft rejections. The incidences of acute grades III\u2013IV and extensive chronic GVHD were 15%/47% (MRD), 8%/60% (URD), and 10%/31% (Haplo). There were no statistically significant differences in the ability to discontinue immunosuppression based on donor cell sources. With a median follow up of 20 (range, 4\u201391) months for living pts; the 18 month overall survivals (OS), progression free survivals (PFS), and incidences of relapse/progressive disease (PD) were 47%, 20%, and 55% (MRD), 74%, 27%, and 65% (URD), and 71%, 60%, and 35% (Haplo), respectively. Nonrelapse mortalities (NRM) were significantly lower for URD (HR 0.16; p=0.03) and Haplo (HR 0.13; p=0.02) recipients compared to MRD recipients. There were also significantly decreased risks of relapse for Haplo recipients compared to MRD (HR 0.35; p=0.03) and URD (HR 0.36; p=0.02) recipients. These data suggest that salvage allogeneic HCT using nonmyeloablative conditioning provides anti-tumor activity in pts with very advanced disease; however, Rel/PD continue to be major problems regardless of stem cell source. Importantly, alternative donor sources are a viable option particularly for those pts who may have a limited window of opportunity to proceed to HCT. Pt Characteristics  . . MRD (n=34) . URD (n=24) . Haplo (n=21) . Median Age (yrs)  33 28 31 Disease Status at HCT CR 11 (32%) 5 (21%) 5 (24%)  PR 16 (47%) 8 (33%) 5 (24%)  Rel/Ref 7 (21%) 11 (46%) 11 (52%) Disease Bulk > 5cm  3 (9%) 3 (13%) 3 (14%) HCT-Comorbidity Index >2  21 (62%) 17 (74%) 13 (62%) Regimens > 5  16 (47%) 16 (67%) 12 (57%) Failed Prior Auto HCT  30 (88%) 23 (96%) 19 (90%) Median Time Diagnosis - Allo HCT (months)  33 31 32 Median Time Auto-Allo HCT (months)  16 19 17 . . MRD (n=34) . URD (n=24) . Haplo (n=21) . Median Age (yrs)  33 28 31 Disease Status at HCT CR 11 (32%) 5 (21%) 5 (24%)  PR 16 (47%) 8 (33%) 5 (24%)  Rel/Ref 7 (21%) 11 (46%) 11 (52%) Disease Bulk > 5cm  3 (9%) 3 (13%) 3 (14%) HCT-Comorbidity Index >2  21 (62%) 17 (74%) 13 (62%) Regimens > 5  16 (47%) 16 (67%) 12 (57%) Failed Prior Auto HCT  30 (88%) 23 (96%) 19 (90%) Median Time Diagnosis - Allo HCT (months)  33 31 32 Median Time Auto-Allo HCT (months)  16 19 17 View Large Outcomes by donor type    MRD (n=34) URD (n=24) Haplo (n=21) Median f/u living pts months (range)  15 (4\u201391) 26 (8\u201358) 15 (4\u201349) Acute GVHD grade II\u2013IV, III\u2013IV  53%, 15% 50%, 8% 43%, 10% 18 month extensive chronic GVHD  47% 60% 31% Day 200 NRM  18% 0% 0% 18 month OS 47% 74% 71%  NRM 25% 8% 5%  Rel/PD 55% 65% 35%  PFS 20% 27% 60%   MRD (n=34) URD (n=24) Haplo (n=21) Median f/u living pts months (range)  15 (4\u201391) 26 (8\u201358) 15 (4\u201349) Acute GVHD grade II\u2013IV, III\u2013IV  53%, 15% 50%, 8% 43%, 10% 18 month extensive chronic GVHD  47% 60% 31% Day 200 NRM  18% 0% 0% 18 month OS 47% 74% 71%  NRM 25% 8% 5%  Rel/PD 55% 65% 35%  PFS 20% 27% 60% View Large",
    "topics": [
        "allogeneic hematopoietic stem cell transplant",
        "allopurinol",
        "brachial plexus neuritis",
        "calcineurin inhibitors",
        "conditioning (psychology)",
        "cyclophosphamide",
        "donors",
        "fludarabine",
        "follow-up",
        "graft-versus-host disease"
    ],
    "author_names": [
        "Lauri Burroughs",
        "Paul O\u2019Donnell",
        "Brenda M. Sandmaier",
        "Barry Storer",
        "Leo Luznik",
        "Heather Symons",
        "Michael Maris",
        "Karl G. Blume",
        "Dietger W. Niederwieser",
        "Benedetto Bruno",
        "Richard T. Maziarz",
        "Michael Pulsipher",
        "Finn Petersen",
        "Peter A. McSweeney",
        "Thomas Chauncey",
        "Edward Agura",
        "James C. Wade",
        "Rainer F. Storb",
        "Ephraim J. Fuchs",
        "David G. Maloney"
    ],
    "author_dict_list": [
        {
            "author_name": "Lauri Burroughs",
            "author_affiliations": [
                "Fred Hutchinson Cancer Res Ctr"
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Paul O\u2019Donnell",
            "author_affiliations": [
                "Fred Hutchinson Cancer Res Ctr"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Brenda M. Sandmaier",
            "author_affiliations": [
                "Fred Hutchinson Cancer Res Ctr"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Barry Storer",
            "author_affiliations": [
                "Fred Hutchinson Cancer Res Ctr"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Leo Luznik",
            "author_affiliations": [
                "John Hopkins"
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Heather Symons",
            "author_affiliations": [
                "John Hopkins"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Michael Maris",
            "author_affiliations": [
                "Rocky Mountain Blood & Marrow Transplantation"
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Karl G. Blume",
            "author_affiliations": [
                "Stanford U."
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Dietger W. Niederwieser",
            "author_affiliations": [
                "U. of Leipzig"
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Benedetto Bruno",
            "author_affiliations": [
                "U.of Torino"
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Richard T. Maziarz",
            "author_affiliations": [
                "Oregon Health & Science U."
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Michael Pulsipher",
            "author_affiliations": [
                "U. of Utah"
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Finn Petersen",
            "author_affiliations": [
                "Intermountain Blood & Marrow Transplant Program"
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Peter A. McSweeney",
            "author_affiliations": [
                "Rocky Mountain Blood & Marrow Transplantation"
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Thomas Chauncey",
            "author_affiliations": [
                "Seattle VA Med. Ctr"
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Edward Agura",
            "author_affiliations": [
                "Baylor U."
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "James C. Wade",
            "author_affiliations": [
                "Medical College of Wisconsin"
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Rainer F. Storb",
            "author_affiliations": [
                "Fred Hutchinson Cancer Res Ctr"
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ephraim J. Fuchs",
            "author_affiliations": [
                "John Hopkins"
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "David G. Maloney",
            "author_affiliations": [
                "Fred Hutchinson Cancer Res Ctr"
            ],
            "author_rank": 20,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-04T09:42:02",
    "is_scraped": "1"
}